Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Machine learning for anxiety and depression profiling and risk assessment in the aftermath of an emergency

  • Villanueva Benito, Guillermo
  • Goldberg, Ximena|||0000-0001-9681-5826
  • Brachowicz, Nicolai
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Blay, Natalia|||0000-0002-7160-8529
  • Espinosa, Ana|||0000-0001-7399-3267
  • Davidhi, Flavia
  • Torres, Diego
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • de Cid, Rafael|||0000-0003-3579-6777
  • Petrone, Paula Marcela
Background & objectives: Mental health disorders pose an increasing public health challenge worsened by the COVID-19 pandemic. The pandemic highlighted gaps in preparedness, emphasizing the need for early identification of at-risk groups and targeted interventions. This study aims to develop a risk assessment tool for anxiety, depression, and self-perceived stress using machine learning (ML) and explainable AI to identify key risk factors and stratify the population into meaningful risk profiles. Methods: We utilized a cohort of 9291 individuals from Northern Spain, with extensive post-COVID-19 mental health surveys. ML classification algorithms predicted depression, anxiety, and self-reported stress in three classes: healthy, mild, and severe outcomes. A novel combination of SHAP (SHapley Additive exPlanations) and UMAP (Uniform Manifold Approximation and Projection) was employed to interpret model predictions and facilitate the identification of high-risk phenotypic clusters. Results: The mean macro-averaged one-vs-one AUROC was 0.77 (± 0.01) for depression, 0.72 (± 0.01) for anxiety, and 0.73 (± 0.02) for self-perceived stress. Key risk factors included poor self-reported health, chronic mental health conditions, and poor social support. High-risk profiles, such as women with reduced sleep hours, were identified for self-perceived stress. Binary classification of healthy vs. at-risk classes yielded F1-Scores over 0.70. Conclusions: Combining SHAP with UMAP for risk profile stratification offers valuable insights for developing effective interventions and shaping public health policies. This data-driven approach to mental health preparedness, when validated in real-world scenarios, can significantly address the mental health impact of public health crises like COVID-19.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex-specific chrono-nutritional patterns and association with body weight in a general population in Spain (GCAT study)

  • Pons-Muzzo, Luciana
  • de Cid, Rafael|||0000-0003-3579-6777
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Straif, Kurt
  • Papantoniou, Kyriaki|||0000-0002-0340-9659
  • Santonja, Isabel|||0000-0002-6736-7988
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Palomar-Cros, Anna|||0000-0001-8151-9290
  • Lassale, Camille|||0000-0002-9340-2708
Background: Altered meal timing patterns can disrupt the circadian system and affect metabolism. Our aim was to describe sex-specific chrono-nutritional patterns, assess their association with body mass index (BMI) and investigate the role of sleep in this relationship. Methods: We used the 2018 questionnaire data from the population-based Genomes for Life (GCAT) (n = 7074) cohort of adults aged 40-65 in Catalonia, Spain, for cross-sectional analysis and its follow-up questionnaire data in 2023 (n = 3128) for longitudinal analysis. We conducted multivariate linear regressions to explore the association between mutually adjusted meal-timing variables (time of first meal, number of eating occasions, nighttime fasting duration) and BMI, accounting for sleep duration and quality, and additional relevant confounders including adherence to a Mediterranean diet. Finally, cluster analysis was performed to identify chrono-nutritional patterns, separately for men and women, and sociodemographic and lifestyle characteristics were compared across clusters and analyzed for associations with BMI. Results: In the cross-sectional analysis, a later time of first meal (β 1 h increase = 0.32, 95% CI 0.18, 0.47) and more eating occasions (only in women, β 1 more eating occasion = 0.25, 95% CI 0.00, 0.51) were associated with a higher BMI, while longer nighttime fasting duration with a lower BMI (β 1 h increase=-0.27, 95% CI -0.41, -0.13). These associations were particularly evident in premenopausal women. Longitudinal analyses corroborated the associations with time of first meal and nighttime fasting duration, particularly in men. Finally, we obtained 3 sex-specific clusters, that mostly differed in number of eating occasions and time of first meal. Clusters defined by a late first meal displayed lower education and higher unemployment in men, as well as higher BMI for both sexes. A clear "breakfast skipping" pattern was identified only in the smallest cluster in men. Conclusions: In a population-based cohort of adults in Catalonia, we found that a later time of first meal was associated with higher BMI, while longer nighttime fasting duration associated with a lower BMI, both in cross-sectional and longitudinal analyses.
Repisalud
Publication Artículo científico (JournalArticle)

Mammographic density and breast cancer in women from high risk families

  • Ramón Y Cajal, Teresa
  • Chirivella, Isabel
  • Miranda, Josefa
  • Teule, Alexandre
  • Izquierdo, Angel
  • Balmaña, Judith
  • Sánchez-Heras, Ana Beatriz
  • Llort, Gemma
  • Fisas, David
  • Lope Carvajal, Virginia
  • Hernandez-Agudo, Elena
  • Juan-Fita, María José
  • Tena, Isabel
  • Robles, Luis
  • Guillén-Ponce, Carmen
  • Pérez-Segura, Pedro
  • Luque-Molina, Mari Sol
  • Hernando-Polo, Susana
  • Salinas, Mónica
  • Brunet, Joan
  • Salas-Trejo, Dolores
  • Barnadas, Agustí
  • Pollan-Santamaria, Marina
INTRODUCTION: Mammographic density (MD) is one of the strongest determinants of sporadic breast cancer (BC). In this study, we compared MD in BRCA1/2 mutation carriers and non-carriers from BRCA1/2 mutation-positive families and investigated the association between MD and BC among BRCA1/2 mutation carriers per type of mutation and tumor subtype. METHODS: The study was carried out in 1039 female members of BRCA1 and BRCA2 mutation-positive families followed at 16 Spanish Genetic Counseling Units. Participants' density was scored retrospectively from available mammograms by a single blinded radiologist using a 5-category scale (<10 %, 10-25 %, 25-50 %, 50-75 %, >75 %). In BC cases, we selected mammograms taken prior to diagnosis or from the contralateral breast, whereas, in non-cases, the last screening mammogram was evaluated. MD distribution in carriers and non-carriers was compared using ordinal logistic models, and the association between MD and BC in BRCA1/2 mutation carriers was studied using logistic regression. Huber-White robust estimators of variance were used to take into account correlations between family members. A similar multinomial model was used to explore this association by BC subtype. RESULTS: We identified and scored mammograms from 341 BRCA1, 350 BRCA2 mutation carriers and 229 non-carriers. Compared to non-carriers, MD was significantly lower among BRCA2 mutation carriers (odds ratio (OR) =0.71; P-value=0.04), but not among BRCA1 carriers (OR=0.84; P-value=0.33). MD was associated with subsequent development BC (OR per category of MD=1.45; 95 % confidence interval=1.18-1.78, P-value<0.001), with no significant differences between BRCA1 and BRCA2 mutation carriers (P-value=0.48). Finally, no statistically significant differences were observed in the association of MD with specific BC subtypes. CONCLUSIONS: Our study, the largest to date on this issue, confirms that MD is an independent risk factor for all BC subtypes in either BRCA1 and BRCA2 mutation carriers, and should be considered a phenotype risk marker in this context.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

BN nanosheets reinforced zirconia composites: An in-depth microstructural and mechanical study

  • Muñoz Ferreiro, C.
  • Reveron, H.
  • Rojas, T. C.
  • Fernández de los Reyes, Daniel
  • Cottrino, S.
  • Moreno, P.
  • Prada Rodrigo, J.
  • Morales Rodríguez, A.
  • Chevalier, J.
  • Gallardo López, Á.
  • Poyato, R.
This paper deals with the effect of hydroxylated boron nitride nanosheets (BNNS) incorporation on the microstructural and mechanical features of zirconia ceramics. Few-layered BNNS were synthesized via a simple hydroxide-assisted planetary ball milling exfoliation technique. 3 mol% yttria tetragonal zirconia polycrystal (3Y-TZP) with 2.5 vol% BNNS powders were prepared by an environmentally friendly process in water, and spark-plasma sintered at three temperatures to explore the in-situ reduction of the functionalized BNNS. An exhaustive study by (S)TEM techniques was performed to elucidate the influence of the sintering temperature on the matrix and the 3Y-TZP/BNNS interfaces, revealing that BNNS were homogeneously distributed throughout the matrix with an abrupt transition at 3Y-TZP/BNNS interfaces. BNNS effectively hindered slow crack growth, thus increasing the composite’s crack growth resistance by about 30 %. A 1 MPa⋅m1/2 rising R-curve was also induced by crack bridging.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

  • Sideli, Lucia
  • Aas, Monica
  • Quattrone, Diego
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Alameda, Luis
  • Velthorst, Eva
  • Trotta, Giulia
  • Tripoli, Giada
  • Schimmenti, Adriano
  • Fontana, Andrea
  • Gayer-Anderson, Charlotte
  • Stilo, Simona
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D’Andrea, Giuseppe
  • EU-GEI WP2 Group
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Rossi Menezes, Paulo
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • Haan, Lieuwe de
  • Selten, Jean-Paul
  • Os, Jim van
  • Rutten, Bart P. F.
  • Bentall, Richard
  • Di Forti, Marta
  • Murray, Robin M.
  • Morgan, Craig
  • Fisher, Helen L.
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., This study investigated if the association between childhood maltreatment and cognition among psychosis patients and community controls was partially accounted for by genetic liability for psychosis. Patients with first-episode psychosis (N = 755) and unaffected controls (N = 1219) from the EU-GEI study were assessed for childhood maltreatment, intelligence quotient (IQ), family history of psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). Controlling for FH and SZ-PRS did not attenuate the association between childhood maltreatment and IQ in cases or controls. Findings suggest that these expressions of genetic liability cannot account for the lower levels of cognition found among adults maltreated in childhood., We are grateful to the EU-GEI study participants for their essential contribution to this project. The EU-GEI Study is funded by grant agreement HEALTH-F2-2010–241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417–0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. D. Quattrone is supported by the Medical Research Council Clinical Academic Research Partnership [MR/W030608/1]. M. Aas is supported by an MRC fellowship (#MR/WO27720/1). C. Arango has received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union—NextGenerationEU (PMP21/00051, PI19/01024), CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (Project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. The views expressed are those of the authors and not necessarily those of the ESRC or King’s College London., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences

  • Arango, Celso
  • Baeza, Inmaculada
  • García-Rizo, Clemente
  • Crespo-Facorro, Benedicto
  • Lahera, Guillermo
  • Vieta, Eduard
  • Becker, Frauke
  • Dwyer, Georges
  • Bourke, Siobhan
  • Gibson, Adam
  • Gabarda-Inat, Irene
  • Álvarez-Baron, Elena
The abstract of this paper was presented at the 36th ECNP Congress 2023 (Barcelona 7-10 October) as a poster presentation with interim findings. The poster’s abstract was published in Abstracts of the 36th ECNP Congress 2023 in Neuroscience applied (Vol2, Supplement 2): https://doi.org/10.1016/j.nsa.2023.103062., [Purpose:] Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients’ health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects., [Patients and Methods:] This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain. Stage 1 included qualitative and quantitative elements (including included two validated patient-reported outcome measures: PETiT and EQ-5D-5L) administered in telephone interviews with people with schizophrenia. Stage 2 consisted of a quantitative online survey completed by people with schizophrenia attending outpatient clinics. Responses to quantitative items across both stages were combined for analysis., [Results:] Twenty respondents completed the mixed methods interviews (stage 1), and 25 participants completed the online survey (stage 2). Results from stages 1 and 2, showed that participants perceived treatments to have a beneficial impact on controlling their symptoms. However, cognitive side effects were reported to have a detrimental impact on respondents’ daily life and were considered a primary reason for treatment cessation in the past. Qualitative findings further showed that most participants hoped future treatments would minimise the impact of cognitive symptoms of schizophrenia., [Conclusion:] The findings suggest that patients’ expectation around treatment efficacy and their acceptability of treatment side effects may indicate their capacity to maintain long-term treatment adherence. Trade-offs that patients may be willing to make between these components may prove useful to consider in clinical practice to improve treatment adherence and hence treatment effectiveness in people with schizophrenia., CA has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI22-01824.CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. IB has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (PI21/0391), co-financed by the European Union, Drugs National Plan (2022I053) and Fundación Alicia Koplowitz., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Biological underpinnings and genetic predisposition to schizophrenia within microrna-137 regulatory pathways across brain development

  • Stella, Carol
  • Hoyos, Lucía de
  • Mora, Alberto
  • Díaz-Caneja, Covadonga M.
  • Andreu-Bernabeu, Álvaro
  • Costas, Javier
  • Gurriarán, Xaquín
  • Fañanas, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Vázquez-Bourgon, Javier
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Sánchez-Gistau, Vanessa
  • Moltó, Maria Dolores
  • Rivero, Olga
  • CIBERSAM consortium
  • Arango, Celso
  • González-Peñas, Javier
[Data availability] GWAS summary datasets used in this study have been downloaded from the PGC repository (https://www.med.unc.edu/pgc/download-results/). Gene expression data from brain developmental trajectories (http://www.brainspan.org/) and adult brain (https://gtexportal.org/home/) were downloaded from FUMA platform (https://fuma.ctglab.nl/). Individual genotype data for the CIBERSAM consortium samples (Spain, https://www.cibersam.es/en) used here and analytic code are available from the corresponding author upon reasonable request, since deposit of this data to a public repository is not allowed due to ethical and legal requirements at the participating centers., Previous studies have evaluated the role of the microRNA-137 (miRNA137) regulatory pathway in schizophrenia by using in silico or in vitro predicted target genes. These approaches do not capture the dynamic spatiotemporal nature of the miRNA137 regulatory pathway or tend to overestimate direct miRNA binding sites. To provide a more accurate representation of the miRNA137 pathway during human brain development, we evaluated the biological functionality of direct ex vivo miRNA137 targets previously documented in the early prenatal and adult brain. We studied the role of differential expression and genetic predisposing variation to schizophrenia and related disorders within these miRNA137 targets by gene set enrichment analyses (GSEA) and gene-set based polygenic score predictions in an independent schizophrenia case-control cohort. All results were compared to those from in silico or in vitro predicted targets. Only direct miRNA137 targets at prenatal and adult human brain displayed significant enrichments in synaptic and neuronal functions and captured the transcriptomic and genetic predisposing variation to schizophrenia. Furthermore, while adult target genes showed a more consistent enrichment in predisposing variation to schizophrenia and bipolar disorder in case/control polygenic models, prenatal target genes predicted negative symptomatology in schizophrenia patients. Our results suggest that using direct, temporally specific miRNA137 targets significantly improved the detection of biological mechanisms underlying its relationship with psychosis, clarified the association between schizophrenia and related conditions, and suggested association with specific symptomatology domains at different developmental stages of the disorder., Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI23/00625), the European Union -NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394)) European Union Horizon Europe Program (Project Youth-GEMs (Grant agreement No 101057182), the National Institute of Mental Health of the National Institutes of Health, Fundación Familia Alonso, and Fundación Alicia Koplowitz. González-Peñas held a Sara Borrell and a Miguel Servet grant during the development of the research from Instituto de Salud Carlos III (CD20/00118; CP24/00080-DOS). CM Díaz-Caneja has previously held a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (JR19/00024)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Torrens, Laura
  • Simón-Coma, Marina
  • Royo, Laura|||0000-0001-5770-2001
  • Domingo-Sàbat, Montse|||0000-0001-6687-3259
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Akers, Nicholas
  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Ragull, Sonia
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Kappler, Roland
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Guerra Pastrian, Laura|||0000-0002-8478-8522
  • Sábado, Constantino|||0000-0003-3956-5466
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Piñeyro, David|||0000-0001-5633-3339
  • Vázquez-Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa|||0000-0001-9659-1471
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López-Ibor, Blanca
  • López-Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià|||0000-0002-2225-0217
  • Paris, Claudia
  • Bajčiová, Viera
  • Laureys, Geneviève
  • Masnou, Helena|||0000-0003-0632-1393
  • Clos, Ariadna|||0000-0002-6414-2097
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Guettier, Catherine
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Planas, Ramón
  • Jordà, Mireia|||0000-0003-3709-1850
  • Nonell, Lara|||0000-0002-8538-8213
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela|||0000-0002-9000-611X
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Armengol, Carolina|||0000-0002-4690-4027
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David|||0000-0001-7930-0935
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Meers, Oliver|||0000-0001-9532-7767
  • Garcia-Jaraquemada, Arce|||0000-0001-6603-2003
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Valero, Vanesa
  • Pérez, Ainoha
  • Del Río-Álvarez, Álvaro|||0000-0003-2338-0782
  • Royo, Laura|||0000-0001-5770-2001
  • Pérez-González, Beatriz|||0000-0001-9849-5176
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Acemel, Rafael D.|||0000-0003-4120-0140
  • Santos-Pereira, José M.|||0000-0003-3949-0644
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Gómez-Skarmeta, José Luís|||0000-0001-5125-4332
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Manyé, Josep|||0000-0002-3121-8016
  • Armengol, Carolina|||0000-0002-4690-4027
  • Buschbeck, Marcus|||0000-0002-3218-4567
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment.